Results of the Annual General Meeting held on 25 May 2017

May 25, 2017 at 4:55 PM

Results of the Annual General Meeting held on 25 May 2017 at the offices of Clifford Chance LLP, 10 Upper Bank Street, London E14 5JJ. 

Chippenham, UK, 25 May 2017: Vectura Group plc (LSE: VEC; "Vectura" or "the Company"), announces that all resolutions proposed to shareholders at its Annual General Meeting held today were duly passed on a poll, the results of which are set out below:

 

 Resolution

Votes for

% of votes cast

Votes against

% of votes cast

Votes withheld*

1

To   receive the Company’s Report and Accounts for the nine months ended 31 December   2016 including the independent auditor’s report

539,565,737

97.43

14,208,182

2.57

29,991

2

To   approve the Directors' Remuneration Policy

518,828,772

96.56

18,505,659

3.44

16,469,480

3

To   receive and approve the Directors' Remuneration Report for the nine months   ended 31 December 2016 (excluding the Remuneration Policy)

522,296,809

95.78

23,001,558

4.22

8,505,545

4

To   re-elect Dr P Andersson

550,427,165

99.40

3,296,566

0.60

80,182

5

To   re-elect Bruno Angelici

545,863,232

98.64

7,504,313

1.36

436,369

6

To re-elect   Frank Condella

521,328,310

94.15

32,395,663

5.85

79,942

7

To re-elect   Andrew Derodra

545,489,090

98.51

8,223,282

1.49

91,544

8

To   re-elect Dr Susan Foden

526,562,922

98.10

10,219,297

1.90

17,021,698

9

To re-elect   James Ward-Lilley

548,000,029

98.97

5,712,651

1.03

91,238

10

To   re-elect Neil Warner

552,862,847

99.84

861,229

0.16

79,843

11

To re-elect   Dr Thomas Werner

553,222,872

99.91

490,055

0.09

90,993

12

To   appoint KPMG LLP as the Company’s Auditor

553,609,848

99.97

166,125

0.03

27,948

13

To   authorise the Audit Committee to determine the auditor’s remuneration

553,687,129

99.98

109,800

0.02

6,993

14

To   authorise political donations and expenditure

532,550,792

96.17

21,184,033

3.83

68,757

15

To authorise   the Directors to allot shares in the Company pursuant to section 551 of the   Companies Act 2006

537,069,120

96.99

16,680,629

3.01

35,688

16

To   approve the Rules of the Deferred Share Bonus Plan

543,417,948

98.13

10,331,467

1.87

54,510

17

To authorise   the disapplication of pre-emption rights

547,458,293

98.87

6,284,433

1.13

61,200

18

To authorise   the disapplication of pre-emption rights in relation to an acquisition or   other capital investment

507,736,477

91.69

46,006,450

8.31

61,000

19

To   authorise market purchases of the Company’s own shares

544,461,196

98.31

9,334,145

1.69

8,587

20

To   authorise the calling of any general meetings of the Company other than an   Annual General Meeting by notice of at least 14 clear days

546,503,889

98.68

7,297,055

1.32

2,537

*NB: The percentage of votes cast for and against excludes withheld votes.

Enquiries:

Vectura Group plc  
+44 (0)1249 667700
  
John Murphy
Company Secretary
 
One Prospect West
Chippenham
Wiltshire SN14 6FH
 
Consilium Strategic Communications    
+44 (0)20 3709 5700

Mary-Jane Elliot / Sue Stuart / Jessica Hodgson

Notes for Editors:

About Vectura

Vectura, a FTSE250 company listed on the London Stock Exchange (LSE: VEC), is an industry-leading inhaled airways disease focused business with proprietary formulation and devices across DPI, pMDI and smart nebulisation platforms. With our extensive range of technologies, capabilities and collaborations, we believe we can become a leader in the development of inhalation products, increasing our ability to help patients suffering from respiratory diseases.  In June 2016 Vectura completed a merger with Skyepharma PLC.

Vectura has seven inhaled, four non-inhaled and ten oral products marketed by partners with growing global royalty streams, and a portfolio of drugs in clinical development, a number of which have licence agreements with several global pharmaceutical and biotechnology companies including Hikma, Novartis, Sandoz, Mundipharma, Kyorin, Baxter, GSK, UCB, Ablynx, Grifols, Chiesi, Almirall, Janssen, and Tianjin KingYork.

For further information, please visit Vectura's website at www.vectura.com.

 

Tags:
back to top